@article {Raghavan2021.12.13.21267706, author = {Kadalraja Raghavan and Vidyasagar Devaprasad Dedeepiya and Subramaniam Srinivasan and Subramanian Pushkala and Sudhakar Subramanian and Nobunao Ikewaki and Masaru Iwasaki and Rajappa Senthilkumar and Senthilkumar Preethy and Samuel JK Abraham}, title = {Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study}, elocation-id = {2021.12.13.21267706}, year = {2021}, doi = {10.1101/2021.12.13.21267706}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder causing progressive muscle weakness and premature death. Steroids remain the mainstream approach for supportive care but have side effects; other targeted therapies and gene therapies are also being developed. As there is limited evidence on the use of disease-modifying nutritional supplement adjuncts in DMD, this pilot trial is to evaluate the effects of supplementation of Aureobasidium pullulans-derived 1,3-1,-6 beta glucan from the N-163 strain in young patients with DMD.Methods Twenty-seven patients with Duchenne muscular dystrophy (DMD){\textemdash}nine in the control arm (undergoing conventional therapies){\textemdash}participated. The patients were divided into groups: those not administered steroids (Steroid -ve) (n = 5), those administered steroids (Steroid +ve) (n = 4), and 18 in the treatment arm (N-163 beta glucan supplement along with conventional therapies; N-163 Steroid {\textendash}ve and N-163 Steroid +ve); they participated in the study for 45 days. Assessments of muscle function, disease status, and levels of IL-6, IL-13, TGF-β, creatinine kinase (CK), titin, TNF-α, haptoglobin, and dystrophin in the blood and myoglobin in the urine were performed at baseline and at the end of the study.Results IL-6 showed a significant decrease in the N-163 Steroid -ve group, from a baseline value of 7.2 {\textpm} 1.2 pg/ml to 2.7 {\textpm} 0.03 pg/ml. IL-13 decreased in both treatment groups{\textemdash}from 157.76 {\textpm} 148.68 pg/ml to 114.08 {\textpm} 81.5 pg/ml (N-163 Steroid -ve) and from 289.56 {\textpm} 232.88 pg/ml to 255.56 {\textpm} 214.13 pg/ml (N-163 Steroid +ve). TGF-β levels showed a significant decrease in the N-163 Steroid {\textendash}ve group, from a baseline value of 3302 {\textpm} 1895 ng/ml to 1325.66 {\textpm} 517 ng/ml post intervention. Dystrophin levels increased by up to 32\% in both Steroid +ve and -ve groups. Medical research council (MRC) grading showed muscle strength improvement in 12 out of 18 patients (67\%) in the treatment group and four out of nine (44\%) subjects in the control group.Conclusion Supplementation with the N-163 beta glucan food supplement produced disease-modifying beneficial effects: a significant decrease in inflammation and fibrosis markers, increase in dystrophin and improvement in muscle strength in DMD subjects over 45 days, thus making this a potential adjunct treatment for DMD after validation. A longer duration of follow-up and further research on the mechanism of action and commonalities with other diseases provoked by hyperactive inflammation and/or fibrosis may pave the way for their extended applications in other dystrophinopathies and neuroinflammatory diseases.Trial registration Clinical trials registry of India, CTRI/2021/05/033346. Registered on 5 May, 2021.Competing Interest StatementAuthor Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.Clinical TrialClinical trials registry of India, CTRI/2021/05/033346Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript}, URL = {https://www.medrxiv.org/content/early/2021/12/14/2021.12.13.21267706}, eprint = {https://www.medrxiv.org/content/early/2021/12/14/2021.12.13.21267706.full.pdf}, journal = {medRxiv} }